Aggregate value of units actually supplied.

No definition available.

Name:	olma_AggregateValueOfUnitsActuallySupplied
Namespace Prefix:	olma_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

In the aggregate, the maximum milestone payments to be paid to the collaborative partner.

+ References

No definition available.

+ Details

Name:	olma_CollaborativeArrangementAggregateMaximumMilestonePaymentsToBePaidToCollaborativePartner
Namespace Prefix:	olma_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Exclusive negotiation period after receipt of written notice.

+ References

No definition available.

+ Details

Name:	olma_ExclusiveNegotiationPeriodAfterReceiptOfWrittenNotice
Namespace Prefix:	olma_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Exclusive negotiation period maximum.

+ References

No definition available.

+ Details

Name:	olma_ExclusiveNegotiationPeriodMaximum
Namespace Prefix:	olma_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of patients.

+ References

No definition available.

+ Details

Name:	olma_NumberOfPatients
Namespace Prefix:	olma_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Proposed sale negotiation period.

+ References

No definition available.

+ Details

Name:	olma_ProposedSaleNegotiationPeriod
Namespace Prefix:	olma_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

It represent expenses related to upfront research and development.

+ References

No definition available.

+ Details

Name:	olma_UpfrontPaymentResearchAndDevelopmentExpenses
Namespace Prefix:	olma_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-9

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 720
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483359/720-20-50-1

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 27
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482395/460-10-55-27

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482425/460-10-50-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-1

+ Details

Name:	us-gaap_LossContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-18

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=olma_TwoThousandTwentyFourNovartisAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=olma_TwoThousandAndTwentyNovartisAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=olma_BioMedicalResearchIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=olma_AurigeneAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	olma_MilestoneAchievementAxis=olma_CommercialMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	olma_MilestoneAchievementAxis=olma_ClinicalDevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=olma_TwoThousandAndTwentySixBayerAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies - Additional Information (Details) $ in Thousands		1 Months Ended	3 Months Ended		6 Months Ended
	Nov. 29, 2024 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2026 USD ($) Item	Jun. 30, 2025 USD ($)	Jun. 30, 2026 USD ($) Item	Jun. 30, 2025 USD ($)
Loss Contingencies [Line Items]
Research and development			$ 57,785	$ 43,902	$ 107,017	$ 74,526
2024 Novartis Agreement
Loss Contingencies [Line Items]
Exclusive negotiation period after receipt of written notice	30 days
Exclusive negotiation period maximum	120 days
Proposed sale negotiation period	45 days
Aggregate amount of units actually supplied	$ 275,000
2020 Novartis Agreement \| Bio Medical Research Inc
Loss Contingencies [Line Items]
Number of patients \| Item			60		60
Aurigene Agreement
Loss Contingencies [Line Items]
Milestone payments to be paid to collaborative partner		$ 60,000
Upfront payment, research and development.		8,000
Aurigene Agreement \| Commercial Milestone
Loss Contingencies [Line Items]
Milestone payments to be paid to collaborative partner		$ 370,000
Aurigene Agreement \| Clinical Development Milestones
Loss Contingencies [Line Items]
Upfront payment, research and development.					$ 23,000
2026 Bayer Agreement \| Bio Medical Research Inc
Loss Contingencies [Line Items]
Number of patients \| Item			36		36